N Engl J Med October 2013 PMID 23992601

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman, Matthew A Cavender, Jacob A Udell, Nihar R Desai, Ofri Mosenzon, Darren K McGuire

Download social card

Mentions

Peak: 1 in Apr 2020

across 5 sources since Apr 2020

Extended reach

8,972

potential audience

Total likes

Video views

383

Mentions per month

Apr 2020 – Jul 2025

Where it's discussed

News24 articles
Facebook21 posts
Blogs9 articles
X / Twitter3 posts
YouTube2 videos

AI synopsis

What people are saying

The social discussions mention key findings such as the lack of significant harm from saxagliptin and the 27% hospitalization rate, using terms like 'safe option' and 'mixed results', showing an interest in balancing safety and risk. The tone remains analytical but moderate, reflecting a cautious engagement with the study's implications.

AgreementNeither agree nor disagree

Most discussions acknowledge the study's results, highlighting safety and mixed outcomes, showing neither full agreement nor disagreement.

InterestModerate interest

Comments indicate a moderate level of curiosity about the cardiovascular effects and safety data, but lack deep engagement.

EngagementNeutral engagement

There is some referencing of specific trials and outcomes, but overall comments are brief and surface-level.

ImpactModerate impact

The discussions suggest the article influences ongoing debates about medication safety but do not seem to drastically change clinical practice or opinions.

Abstract in brief

The study found that saxagliptin, a diabetes medication, did not significantly change the risk of major cardiovascular events like heart attack or stroke compared to a placebo.
Patients taking saxagliptin had a slightly higher rate of hospitalization for heart failure than those on placebo, but rates of pancreatitis were similar in both groups.
Overall, saxagliptin was found to be neither harmful nor beneficial in terms of cardiovascular safety, indicating it is a safe option for managing blood sugar in patients at risk of heart problems.

Read the full abstract

All mentions

Investigating Lixisenatide for Cardiovascular Risks in Type 2 Diabetes Patients

This video discusses a study on lixisenatide, a medication for type 2 diabetes, examining its effects on cardiovascular outcomes in patients with recent heart attacks or unstable angina. The medication was found to be…

Le Relou Des Réseaux · Apr 10, 2020 234 views

Semaglutide's Impact on Weight Loss and Cardiovascular Health Explained

This video breaks down how semaglutide works inside the body. We explore its effects on hunger, blood sugar, and long-term weight loss, along with potential side effects and cardiovascular benefits supported by recent…

Live Longer Live Better · Jul 13, 2025 149 views

tune

@keisuke4713 · X

Nov 24, 2023 · 3,743 followers View post →

cardio-met

@cardiomet_CE · X

24c)

May 11, 2022 · 2 likes · 4,219 followers View post →

Edward Enterprises

@EdwardEnterpri3 · X

Comment on Udell et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696–705 | Diabetes Care https://t.co/FHrt56RJ1I

Jun 1, 2020 · 628 followers View post →